Effectiveness and safety of dual therapy with co-packaged dolutegravir and lamivudine compared to triple therapy as switching strategy in clinical practice
Co-packaged DTG/3TC demonstrated high persistence and virologic suppression rates with a favorable safety profile in clinical practice. Its effectiveness and safety were comparable to DTG-based triple therapy, supporting its use as a cost-effective alternative for treatment-experienced PLWH in resource-limited settings.
Authors
- Ángeles Tisné
- Diego Cecchini (ORCID: https://orcid.org/0000-0002-8545-6132)
- Claudia Migazzi
- Edgardo Bottaro (ORCID: https://orcid.org/0009-0001-0602-5175)
- Isabel Cassetti (ORCID: https://orcid.org/0009-0003-4399-2628)
- Macarena Roel (ORCID: https://orcid.org/0000-0002-2952-1868)
- Brenda Bacelar (ORCID: https://orcid.org/0000-0002-9543-2783)
- M. Bergman
Institutions
- Helios Salud (AR)
- Hospital Británico de Buenos Aires (AR)
Publication Details
- Journal
- Revista Española de Quimioterapia
- Published
- 2025-06-16
- DOI
- https://doi.org/10.37201/req/030.2025
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00